PURPOSE The role of maintenance immunotherapy with anti-CD20 monoclonal antibody rituximab in primary central nervous system lymphoma (PCNSL) is unclear. We retrospectively reviewed the medical records of all immunocompetent adults with newly diagnosed PCNSL treated at our institution between1996 and 2017. METHODS We identified 66 patients who attained complete response (CR) after completion of first-line regimen; 20 received maintenance therapy (maintenance therapy group) and 46 were observed with serial MRI scans without maintenance therapy (no-maintenance therapy group). RESULTS Compared to the surveillance group, there was a significant increase in duration of survival (HR 0.27, 95% CI 0.08-0.98, P = 0.046) in the maintenance therapy group while the reduction in the risk of progression was not significant (HR: 0.61, 95% CI 0.26-1.43, P = 0.259). CONCLUSION We are evaluating the effectiveness of maintenance immunotherapy in PCNSL in a prospective multicenter randomized clinical trial.

中文翻译：

---

维持利妥昔单抗对原发性中枢神经系统淋巴瘤反应时间的影响。

目的尚不清楚抗CD20单克隆抗体利妥昔单抗维持免疫治疗在原发性中枢神经系统淋巴瘤（PCNSL）中的作用。我们回顾性研究了1996年至2017年间在我院接受治疗的所有具有免疫功能的新诊断PCNSL成人的病历。20例接受了维持治疗（维持治疗组），46例接受了不进行维持治疗的连续MRI扫描（无维持治疗组）。结果与监测组相比，维持治疗组的生存期显着增加（HR 0.27，95％CI 0.08-0.98，P = 0.046），而进展风险的降低并不显着（HR： 0.61，95％CI 0.26-1.43，P = 0。259）。结论我们正在一项前瞻性多中心随机临床试验中评估维持性免疫疗法在PCNSL中的有效性。